

FOR IMMEDIATE RELEASE

Sun Pharma reports Q2FY27 results

*Q2 Sales at Rs. 161,000 million up 11.8% YoY
Q2 Adjusted Net profit increased to Rs. 31,620 million*

Mumbai, October 30, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the second quarter ending September 30th, 2026.

Highlights of Q2FY27 consolidated financials*

- Sales at Rs. 161,000 million, a growth of 11.8%.
- Global Innovative Medicines sales at US\$ 356 million, up 6.9% and account for 21.1% of sales.
- EBITDA at Rs. 47,439 million, up 4.8%. EBITDA margin at 29.3%.
- Profit before exceptional items and tax was Rs 44,282 million, up 6.3%.
- Net profit was Rs. 19,885 million, adjusted net profit was Rs. 31,620 million.
- R&D investment was Rs. 7,784 million at 4.8% of sales.

Highlights of H1FY27 consolidated financials*

- Sales at Rs. 312,836 million, a growth of 11.0%.
- Global Innovative Medicines sales stood at US\$ 707 million, up 9.8% and account for 21.5% of sales.
- EBITDA was Rs. 91,616 million, up 3.8%. EBITDA margin was 29.1%.
- Profit before exceptional items and tax was Rs 87,311 million, up 7.0%.
- Net profit was Rs. 48,833 million, adjusted net profit was Rs. 62,515 million, up 2.2%.
- R&D investment was Rs. 16,048 million at 5.1% of sales.

**Growth measured vs same period last financial year*

Kirti Ganorkar, Managing Director of the Company, said, “Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World. Among key developments, Ilumya is now approved in the U.S. for the treatment of adults with active psoriatic arthritis. Unloxcyt’s preferred NCCN recommendation reinforces its durable response and good tolerability in aCSCC. Beyond dermatology, we strengthened our cardiovascular portfolio through the licensing of lerodalcibep, a PCSK9 inhibitor, for markets outside US and China. We have started pre-launch activities across EU.”

Organon Acquisition Update

Integration planning for the Organon acquisition continues to progress across functions and workstreams, in line with plan. Regulatory approvals have now been secured in majority of regions, with the remaining jurisdictions tracking on schedule.

India Formulations

Formulation sales in India were Rs. 55,523 million, up by 17.3% and accounting for 34.5% of total consolidated sales for the quarter. For the first half of the year, sales were Rs. 110,272 million, growing by 16.6%.

Sun Pharma continues to be India’s No. 1 Pharma company, with market share increasing to 8.6% from 8.3%, as per the Pharmarack MAT Sept-2026 report. As per SMSRC (Jul-Sept 2026) report, Sun Pharma is ranked No. 1 by prescriptions in 12 doctor categories. The company launched 14 new products during the quarter and 19 products year to date.

US Formulations

Formulation sales in the US were US\$ 455 million for Q2FY27, registering a decline of 8.2%. US sales accounted for approximately 27% of total consolidated sales. For the first half, sales were US\$ 882 million.

Ilumya is now approved in the U.S. for the treatment of adults with active psoriatic arthritis. As a healthcare provider-administered IL-23 inhibitor, Ilumya offers an additional treatment option for adults with active psoriatic arthritis, particularly those who are unable to self-administer therapy or who may benefit from regular in-office care. The approval was supported by two 52-week, global, multicenter, randomized, double-blind, placebo-controlled Phase 3 studies evaluating the efficacy and safety of the product.

Emerging Markets (EM) Formulations

Emerging Markets Formulations sales were US\$ 350 million for Q2FY27, up by 7.6% and accounted for 20.7% of total consolidated sales. For the first half, sales were US\$ 661 million, growing by 6.0%.

Rest of World (ROW) Formulations

Formulation sales in Rest of World (RoW) markets were US\$ 241 million for Q2FY27, up by 3.1% and accounted for 14.3% of total consolidated sales for the quarter. For the first half, sales were US\$ 460 million, up by 1.5%.

Innovative Medicines

Global Innovative Medicines sales were US\$ 356 million for Q2FY27, up 6.9% and accounted for 21.1% of total consolidated sales for the quarter. For the first half, sales were US\$ 707 million, up by 9.8%.

Active Pharmaceutical Ingredients (API)

For Q2FY27, external sales of API were Rs. 4,889 million, up by 13.7%. For the first half, API sales were Rs. 10,861 million, up by 11.9%. Our API portfolio supports our formulation business and API customers across geographies.

R&D Update

Sun Pharma's R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 561 products while filings for 120 ANDAs await US FDA approval, including 26 tentative approvals. During the quarter, 4 ANDAs were filed, and approval received for 3 ANDAs. Sun's portfolio includes 58 approved NDAs while 12 NDAs await US FDA approval.

Innovative Medicines Pipeline

Candidate	Indication	Current phase	Next milestone
Ilumya	psoriatic arthritis	Approved in the US	Launch
Fibromun	soft tissue sarcoma	Phase 2 completed	Start of Phase 3
	Glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 2	Topline data during 2HCY27
Nidleg TM (EU, ANZ rights with Sun)	locally advanced melanoma	Filing with EMA	Approval and launch
	locally advanced BCC	Phase 3	Regulatory filing
	locally advanced cSCC	Phase 2	Regulatory filing
Candidate for partnering			
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

Sales and R&D snapshot

(Rs in mn)

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
India Formulations	55,522.8	54,748.9	47,347.9	1,10,271.7	94,558.9	1,92,903.6
US Formulations	43,471.0	40,419.1	43,287.9	83,890.1	83,740.0	1,68,242.2
EM Formulations	33,402.5	29,456.3	28,366.9	62,858.8	53,898.3	1,11,864.8
ROW Formulations	23,040.0	20,685.8	20,414.9	43,725.8	39,150.8	85,684.0
Total Formulations	1,55,436.3	1,45,310.1	1,39,417.6	3,00,746.4	2,71,348.0	5,58,694.6
API	4,888.6	5,972.3	4,298.7	10,860.9	9,702.4	21,852.6
Others	675.2	553.1	335.9	1,228.3	862.5	1,653.9
Total Sales	1,61,000.1	1,51,835.5	1,44,052.2	3,12,835.6	2,81,912.9	5,82,201.1
Total R&D Expenditure	7,784.2	8,263.5	7,826.5	16,047.7	16,855.1	35,540.1
Capital	314.2	186.9	145.9	501.1	333.5	799.1
Revenue	7,470.0	8,076.6	7,680.6	15,546.6	16,521.6	34,741.0
Exchange Rates : US\$ 1 = Rs	95.58	94.70	87.35			

Earnings Call (06.30 pm IST, October 30, 2026)

The Company will host earnings call at 06.30 pm IST on October 30, 2026, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible through an audio dial-in and a webcast.

Audio conference

Participants can dial-in on the numbers below

Universal number: +91 22 6629 0049
+91 22 7194 5729

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Pre-registration details Click here [DiamondPassRegistration](#)

Webcast *More details will be provided through our website, www.sunpharma.com*

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available at www.sunpharma.com. The playback will be available for a few days.

Disclaimer

Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world’s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).

Contacts

Investors

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com